An immunotherapy approach with dendritic cells genetically modified to express the tumor-associated antigen, HER2

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2008-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-007-0399-8PMID 17786440PMCID PMC11029918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent vaccine therapy with dendritic cells genetically modified by the gene-silencing-resistant retroviral vector GCDNsap.

  2006cited by this paper
• Stem-cell therapies for blood diseases

  2006cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• Clinical applications of dendritic cell vaccination in the treatment of cancer

  2004cited by this paper
• Immunogene Therapy of Tumors with Vaccine Based on Xenogeneic Epidermal Growth Factor Receptor1

  2003cited by this paper
• Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy.

  2002cited by this paper
• Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.

  2002cited by this paper
• Down-regulation of retroviral transgene expression during differentiation of progenitor-derived dendritic cells.

  2002cited by this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cited by this paper
• Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein

  2002cited by this paper
• Viral vectors for dendritic cell-based immunotherapy.

  2001cited by this paper
• Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100

  2001cited by this paper
• Viral vectors for dendritic cell-based immunotherapy.

  2001cited by this paper
• Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy1

  2001cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.

  1999cited by this paper
• Natural adjuvants: Endogenous activators of dendritic cells

  1999cited by this paper
• Human HER‐2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Immunotherapy of cancer with dendritic-cell-based vaccines

  1998cited by this paper
• Immunotherapy of cancer with dendritic cell-based vaccines

  1998cited by this paper
• gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors

  1997cited by this paper
• A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.

  1996cited by this paper
• Retroviral transduction of human dendritic cells with a tumor-associated antigen gene.

  1996cited by this paper
• Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1).

  1996cited by this paper
• Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

  1995cited by this paper
• Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

  1992cited by this paper
• The dendritic cell system and its role in immunogenicity.

  1991cited by this paper
• The JAM test. A simple assay for DNA fragmentation and cell death.

  1991cited by this paper
• The neu (c-erbB-2) oncogene.

  1989cited by this paper
• Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

  1988cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The neu oncogene encodes an epidermal growth factor receptor-related protein

  1986cited by this paper
• Characterization of EBV‐genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non‐Hodgkin lymphoma

  1977cited by this paper
• Human breast cancer in culture.

  1976influential reference
• Studies in Antibody Response of Mice to Tumour Inoculation

  1950cited by this paper
• Studies in antibody response of mice to tumour inoculation.

  1950cited by this paper

• Risk Factors in Breast Cancer Progression and Current Advances in Therapeutic Approaches to Knockdown Breast Cancer

  2018cites this paper
• Progress in Vaccine Therapies for Breast Cancer.

  2017cites this paper
• Recent advances in the development of breast cancer vaccines

  2014cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium

  2014cites this paper
• Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

  2013cites this paper
• Preclinical HER-2 Vaccines: From Rodent to Human HER-2

  2013cites this paper
• Vaccines and other immunological approaches for cancer immunoprevention.

  2011cites this paper
• A single low dose of dendritic cells modified with lentivirus containing a truncated neu gene can effectively suppress neu‐overexpressing tumors

  2010cites this paper
• Progress in the use of Immunotherapy to Treat Uterine Cervical Cancer

  2009cites this paper
• The induction of tumor‐specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti‐tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells

  2009cites this paper
• Progress in the use of immunotherapy to treat uterine cervical cancer.

  2009cites this paper
• The Role of Myeloid-Derived Suppressor Cells in the Immunotherapy of Breast Carcinomas

  2009cites this paper
• Dendritic Cell Transfected with Secondary Lymphoid-Tissue Chemokine and/or Interleukin-2 Gene-Enhanced Cytotoxicity of T-Lymphocyte in Human Bladder Tumor Cell S In Vitro

  2009cites this paper